DEA Compliance & DEA Consultant Expert
I am Scott Brinks, a nationally recognized DEA compliance and controlled substance diversion expert with more than 28 years of experience in federal law enforcement, DEA regulatory leadership, and healthcare compliance. My career uniquely bridges frontline diversion investigations, executive‑level DEA policy development, and real‑world compliance program design for healthcare and pharmaceutical organizations.
I began my public service career as a Military Police Officer in the United States Army, followed by service as a federal Police Officer with the U.S. Department of Veterans Affairs. In 2001, I joined the Drug Enforcement Administration (DEA) as a Diversion Investigator, where I conducted complex criminal, civil, and regulatory investigations involving pharmaceutical controlled substances and listed chemicals.
For over a decade, I led national and international DEA investigations involving pharmacies, practitioners, manufacturers, distributors, and healthcare systems. These investigations resulted in major indictments, civil settlements, DEA administrative actions, and precedent‑setting enforcement outcomes. My work provided firsthand insight into how diversion is identified, investigated, and prevented—and how compliance failures expose organizations to significant regulatory and reputational risk.
I later served as a DEA Diversion Group Supervisor, transforming underperforming diversion units into top‑rated enforcement teams through data‑driven oversight, investigator training, and accountability. In this role, I supervised complex diversion investigations, DEA audits, and enforcement actions across multiple federal districts while conducting extensive outreach and training for DEA registrants.
In 2017, I transitioned to DEA Headquarters, where I advised DEA leadership and industry on Controlled Substances Act (CSA) compliance, regulatory interpretation, and diversion prevention strategy. This work culminated in my promotion to Section Chief of the DEA Regulatory Drafting and Policy Support Section, where I supervised all federal regulatory drafting for the DEA.
As Section Chief, I led or oversaw 43 Notices of Proposed Rulemaking and Final Rules, including landmark regulations impacting telemedicine, opioid treatment access, suspicious order reporting systems, DEA fees, and diversion prevention. During the COVID‑19 public health emergency, I played a central role in publishing regulatory flexibilities that ensured uninterrupted patient access while maintaining DEA oversight.
In 2024, I founded Brinks DEA Consulting to provide independent DEA compliance consulting informed by real enforcement and regulatory decision‑making experience. I work with healthcare systems, hospitals, pharmacies, manufacturers, distributors, prescribers, and industry associations to design practical solutions that withstand DEA scrutiny.
My consulting services include DEA compliance audits, diversion risk assessments, mock DEA inspections, controlled substance policy development, training programs, and diversion investigation support. I focus not only on regulatory compliance, but on building defensible systems that reduce risk, improve accountability, and protect patient care.
I also serve as Administrator of Diversion Prevention and Engagement for a multi‑facility healthcare system, overseeing enterprise‑wide controlled substance diversion prevention programs and directing more than 300 diversion investigations annually. This ongoing operational role ensures my guidance reflects current healthcare realities—not just regulatory theory.
I hold a Bachelor’s degree in Sociology and a Master’s degree in Pastoral Counseling from Liberty Baptist Theological Seminary, complementing my regulatory expertise with a strong ethics‑based leadership approach. Throughout my career, I have received national recognition for distinguished service, investigative excellence, and leadership.
Today, I help organizations navigate DEA compliance with confidence—combining enforcement insight, regulatory expertise, and practical implementation to reduce risk and protect public health.
Professional Speaking, Training, and Industry Leadership
In addition to my consulting and executive roles, I am a frequent professional speaker and national educator on DEA compliance, controlled substance diversion prevention, and regulatory enforcement trends. Throughout my career with the DEA and in the private sector, I have delivered hundreds of presentations and training programs to audiences across the healthcare and pharmaceutical industries, as well as to federal, state, and local law enforcement agencies.
My speaking experience spans national conferences, executive briefings, industry association events, hospital system leadership sessions, and DEA outreach programs. I have regularly been invited to speak before pharmacists, physicians, healthcare executives, compliance officers, attorneys, manufacturers, distributors, and regulators—often on short notice and in high‑stakes environments where clarity and accuracy matter.
As a former DEA Section Chief and nationally recognized Controlled Substances Act (CSA) subject matter expert, I bring a perspective that few speakers can offer: how DEA policy is developed, how enforcement decisions are made, what regulators actually look for during audits and investigations, and where organizations most often misunderstand or underestimate their compliance risk. I translate complex regulatory requirements into clear, actionable guidance that professionals can apply immediately.
During my tenure at DEA Headquarters, I regularly represented the agency before national trade associations, professional organizations, and regulated industry groups, fostering dialogue between regulators and stakeholders. I played a key role in national initiatives such as practitioner diversion awareness conferences, DEA outreach programs, and industry listening sessions, helping improve understanding, compliance, and collaboration across sectors.
What distinguishes my speaking and training is not theory—it is experience. Every presentation is grounded in real cases, real regulatory decisions, and real consequences seen across pharmacies, hospitals, manufacturers, distributors, and prescriber practices. Participants consistently value my ability to explain why regulators act, how risk is evaluated, and what organizations can do to stay ahead of enforcement rather than simply react to it.
Today, through Brinks DEA Consulting, I continue to provide customized speaking engagements and training programs tailored to executive teams, boards, compliance professionals, clinical staff, and industry conferences. Whether addressing a national audience or a single healthcare system, my goal is the same: to educate, demystify DEA expectations, and help organizations protect patients while maintaining strong, sustainable compliance programs.
My speaking topics commonly include:
- DEA compliance and Controlled Substances Act requirements
- Controlled substance diversion prevention in healthcare systems
- DEA compliance, audits, inspections, and enforcement trends
- Suspicious order monitoring and reporting expectations
- Telemedicine, prescribing, and regulatory risk
- Designing defensible diversion prevention programs
- DEA regulatory changes and policy updates
- Lessons learned from real‑world DEA investigations
- Practitioner Prescribing
Selected Speaking Engagements
- DEA Practitioner Diversion Awareness Conferences
Speaker at multiple national conferences addressing topics including Drugs of Abuse and Trends and Methods of Diversion and Effective Controls for Controlled Substances. - American Conference Institute (ACI) – National Compliance Conferences
Controlled Substances: Regulation, Litigation, and Enforcement Conference
January 26, 2026
Session: “The New DEA Pathway: Operationalizing Special Registration for Virtual Prescribing of Controlled Substances.” - IQVIA – Controlled Substances & State Regulatory Conference
September 3, 2025
Session covering DEA enforcement trends, telemedicine, and controlled substance regulatory requirements. - The Sharing Alliance™ – Pharmaceutical & Biotech Industry Conferences
Session: “DEA – Trends and Updates.” - American Society of Consultant Pharmacists (ASCP) – Annual Conferences
Speaker on topics related to DEA regulations, diversion prevention, and compliance considerations for long‑term‑care facilities. - Center for Telehealth & e‑Health Law (CTeL)
Speaker at conferences, working groups, and briefings for Congressional staffers on topics including telemedicine prescribing, the Ryan Haight Act, and DEA COVID‑era telehealth extensions.
Awards and Recognitions
- DOJ Distinguished Service Award
- NHCAA Investigation of the Year
- DEA Performance Awards (2021–2023)
- DEA Section Chief Leadership Awards
- Army Achievement Medal
- VA Police Officer of the Year
Core Compentenies
- Federal Rulemaking & Regulatory Drafting
- Controlled Substances Act (CSA) & Code of Federal Regulations
- Healthcare Compliance & Risk Mitigation
- Data-Driven Policy Development & AI Integration
- Diversion Prevention in Healthcare, Pharmacy, and Distribution
- Interagency Coordination (DOJ, HHS, OMB, SAMHSA)
- Leadership & Team Building
- Stakeholder Engagement & Coalition Building
- Regulatory Modernization & Change Management